The location of components of fibrinolytic system in laryngeal cancer;Lokalizacja składowych układu fibrynolizy w raku krtani

Polski Merkuriusz Lekarski

Volumn 15, Issue 85, 2003, Pages 81-85

  Sierko, Ewa ^a   Tokajuk, Piotr ^a   Zimnoch, Lech ^a   Wojtukiewicz, Marek Z ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Fibrin; Fibrinolysis; Laryngeal cancer

Indexed keywords

D DIMER; FIBRIN; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CANCER CELL; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MOLECULAR WEIGHT; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; THROMBOEMBOLISM;

ANTIBODIES; CARCINOMA, SQUAMOUS CELL; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0043011310     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alizadeh H. i wsp.: Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr. Eye Res., 1995, 14, 449-458.
2. Bajou K. i wsp.: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 1998, 4, 923-928.
3. Bianchi E. i wsp.: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res., 1994, 54, 861-866.
4. Blasi F.: Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA - u-PAR - PAI-1 system. Thromb. Haemost., 1999, 82, 298-304.
5. Carroll V., Binder B.: The role of the plasminogen activation system in cancer. Sem. Thromb. Haemost., 1999, 25, 183-197.
6. Cohen R. i wsp.: Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood, 1991, 78, 479-487.
7. Collen D.: The plasminogen (fibrinolytic) system. Thromb. Haemost., 1999, 82, 259-270.
8. Constantini V. i wsp.: Occurence of components of fibrinolysis pathways in situ in neoplasmatic human breast tissue. Cancer Res., 1991, 51, 354-358.
9. Duffy M. i wsp.: Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res., 1988, 48, 1348-1349.
10. Foekens J. i wsp.: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J. Natl. Cancer Inst., 1995, 87, 751-756.
11. Foekens J.A. i wsp.: Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer, Cancer Res., 1995, 55, 1423-1427.
12. Ganesh S. i wsp.: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 1994, 54, 4065-4071.
13. Hofmann R. i wsp.: Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer, 1996, 78, 487-492.
14. Liu G., Shuman M., Cohen R.: Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer, 1995, 60, 501-506.
15. Van Muijen G. i wsp.: Properties of metastasizing and nonmetastasizing human melanoma cells. Recent Results Cancer Res., 1995, 139, 105-122.
16. Nasyrov V., Osmonowa R., Rachkol A.: State of the hemostasis system in patients with malignant III-stage neoplasms of the maxilla and larynx. Vestn. Otorinolaringol., 1991, 5, 12-15.
17. Nekarda H. i wsp.: Prognostic impact of urokinase-type plasminogen activator and its inihbitor PAI-1 in completely resected gastric cancer. Cancer Res., 1994, 54, 2900-2907.
18. Ornstein D. i wsp.: Coexistent macrophage procoagulant and tumor cell plasminogen activator in adenocarcinoma and squamous cell carcinoma of the lung. Cancer, 1991, 68, 1061-1067.
19. Pasini F. i wsp.: Transforming growth factor β1, urokinase-type plasminogen activator and plasminogen activator inhibitor - 1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck, 2001, 23, 725-732.
20. Parolini S. i wsp.: Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br. J. Cancer, 1996, 74, 1168-1174.
21. Pawtowska Z. i wsp.: Phosphorothioate oligodeoxyribonucleotides antisense to PAI-1 mRNA increase fibrinolysis and modify experimental thrombosis in rats. Thromb. Haemost., 1998, 79, 348-353.
22. Pedersen H. i wsp.: Urokinase and plasminogen activator inhibitor type I in pulmonary adenocarcinoma. Cancer Res., 1994, 54, 120-123.
23. Pyke C. i wsp.: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol., 1991, 138, 1059-1067.
24. Sato Y. i wsp.: The AmeX method. The simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am. J. Pathol., 1986, 125, 431-435.
25. Sierko E. i wsp.: Czynniki układu hemostazy a angiogeneza w nowotworach. Nowotwory, 2001, 51, 399-409.
26. De Vries T. i wsp.: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol., 1994, 144, 70-81.
27. Wojtukiewicz M.Z. i wsp.: Aktywacja krzepnȩcia krwi u chorych na nowotwory: implikacje kliniczne. Nowotwory, 1999, 49, 381-391.
28. Wojtukiewicz M.Z. i wsp.: Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb. Res., 2000, 97, 335-342.
29. Wojtukiewicz M.Z. i wsp.: Abnormal regulation of coagulation/ fibrinolysis in small cell carcinoma of the lung. Cancer, 1990, 65, 481-485.
30. Wojtukiewicz M.Z. i wsp.: Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am. J. Clin. Pathol., 1990, 93, 516-521.
31. Wojtukiewicz M.Z. i wsp.: The hemostatic system and angiogenesis in malignancy. Neoplasia, 2001, 3, 371-384.
32. Wojtukiewicz M.Z. i wsp.: Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb. Haemost., 1999, 82, 1659-1662.
33. Wojtukiewicz M.Z. i wsp.: Indirect activation of blood coagulation in colon cancer. Thromb. Haemost., 1989, 62, 1062-1066.
34. Zacharski L. i wsp.: The coagulation biology of cancer. Fibrinolysis, 1992, 6, 39-42.
35. Zatoński W. i wsp.: Nowotwory zlośliwe w Polsce w 1995 roku. Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie. Warszawa. 1996, 9-14, 53-55.